



PRESS RELEASE
24 March 2026 13:00:00 CET

Newly elected Chairman Christopher O’Connell and CEO Martin Steinberg to lead the next phase of growth for A3P

A3P Biomedical AB (publ) (“A3P”) announces that the Annual General Meeting has elected Christopher O’Connell as new Chairman of the Board. At the same time, Martin Steinberg, company co-founder and former Chairman of the Board, was appointed Chief Executive Officer and will also continue to serve as a member of the Board.

Christopher O’Connell, who brings more than three decades of global leadership experience in life sciences, has been a member of A3P Biomedical’s Board of Directors since 2025 and will lead the Board in supporting the company’s continued growth and execution.

“I am honoured to have been elected Chairman at this important stage of the company’s development. Stockholm3 represents the most significant advancement in prostate cancer screening in decades. Having served on the Board over the past year, I have seen first hand the strength of the clinical evidence and the commitment of the organization. I look forward to working closely with Martin and the Board to accelerate the company’s international expansion,” says Christopher O’Connell.

Martin Steinberg has played a pivotal role in building A3P and advancing Stockholm3 from scientific innovation to clinical validation and commercial launch and will now manage day-to-day operations and strategy implementation.

“A3P is entering an exciting new phase. With strong clinical validation, and increasing international interest in Stockholm3, the company is well positioned for expansion. Chris brings unmatched global MedTech and Life Science experience and strategic insight as Chairman. In my role as CEO, I look forward to focusing on international growth and operational execution as we work to establish Stockholm3 as the global standard of care for prostate cancer screening,” says Martin Steinberg.

The leadership transition reflects the company’s next stage of development, with strengthened governance and increased focus on global expansion.

Biographies

A3P Biomedical AB (publ)



Christopher O'Connell brings more than three decades of global leadership experience across medical devices, life sciences and global healthcare sectors. He most recently served as CEO and President of Waters Corporation. Prior to that, Christopher O'Connell spent 21 years at Medtronic, where he held various senior leadership positions and was a member of the Executive Committee for nine years. He currently serves as an Independent Director for several innovative companies in medical devices, life sciences, and diagnostics, as well as nonprofit organizations. He holds a Bachelor's degree from Northwestern University, and a Master's degree in Business Administration from Harvard University.

Martin Steinberg co-founded A3P Biomedical AB in 2020 and remains one of the company's largest owners. In addition to leading the company, Martin focuses on business development. He has more than 20 years' experience as an executive and entrepreneur from various industry sectors. His former positions include Investment Manager at the venture capital firm Litorina Kapital and Management Consultancy at Arthur D. Little. Martin Steinberg holds an MBA from the Stockholm School of Economics.

For additional information, please contact:

Cecilia Edström, acting CFO
Telephone: +46 72 226 23 28
Email: cecilia.edstrom@a3p.com

About A3P Biomedical

A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P's main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com



About Stockholm3

Stockholm3 is a blood-based prostate cancer test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.

Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care. Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 41-89% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 37-52% compared to PSA.

Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about Stockholm3 and our clinical studies please visit www.stockholm3.com/

About prostate cancer

Prostate cancer is the most common cancer in men. In 2020, the global incidence of new prostate cancer cases was 1.4 million, and prostate cancer specific mortality 370,000. Global prostate cancer incidence and mortality is expected to rise by 100% and 85% respectively by 2040, driven by an ageing population.

Image Attachments

[Christopher O'Connell Image](#)

Attachments

[Newly elected Chairman Christopher O'Connell and CEO Martin Steinberg to lead the next phase of growth for A3P](#)